Dr. Song to discuss the value of PD-L1 monitoring via liquid biopsy to support immunotherapy treatment choices and targeting.
WESTLAKE VILLAGE, CA – August 31, 2017 – Cynvenio Biosystems, Inc., a leader in liquid biopsy testing technology for personalized medicine, is pleased to announce that Paul Y. Song, M.D., Chief Medical Officer, will deliver a Keynote Presentation, titled “The Role of Liquid Biopsies in Immunotherapy Selection and Monitoring” at the Select Biosciences Liquid Biopsies and Minimally-Invasive Diagnostics 2017 Conference in San Diego, California.
Dr. Song will discuss the need for real-time monitoring of PD-L1 status for more precise patient selection and better outcomes with PD-1/PD-L1 immunotherapy. PD-L1 is part of an adaptive dynamic pathway which can readily change as cancer progresses. Relying solely on the original PD-L1 status of a primary tumor specimen or biopsy may preclude patients who might otherwise benefit from immunotherapy.
Now in its 4th year, the annual Select Biosciences Liquid Biopsies and Minimally-Invasive Diagnostics Conference brings together academic researchers, industry researchers, as well as biotechnology and pharmaceutical companies to explore the expanding and evolving field whereby Circulating Biomarkers of various classes being evaluated for their potential to be developed into diagnostics for cancer as well as other disease classes.
A clinician and researcher with more than two decades of experience in the field of oncology, Dr. Song oversees the translational and clinical research programs at Cynvenio Biosystems, Inc. He also serves as Chief Medial Officer at ATGen where he oversees all clinical aspects of the company’s NK cell activity test. Dr. Song graduated with honors from the University of Chicago and received his M.D. degree from George Washington University. He completed his residency in radiation oncology at the University of Chicago Medical Center and a brachytherapy fellowship at the Institut Gustave Roussy. Dr. Song was also awarded an ASTRO Research Fellowship award by the American Society for Radiation Oncology for his work on radiation induced gene therapy.
Speaker: Paul Y. Song, MD CMO at Cynvenio Biosystems, Inc.
Presentation Title: “The Role of Liquid Biopsies in Immunotherapy Selectionand Monitoring”
Date/Time: Thursday, October 5th, 4:00-4:30 p.m. PST
Event: Liquid Biopsies and Minimally-Invasive Diagnostics 2017
Location: Coronado Island, San Diego, CA
About Cynvenio Biosystems, Inc.
Cynvenio’s liquid biopsy testing technology is leading the way to more affordable and clinically actionable precision medicine strategies for cancer patients. Among the company’s breakthroughs is its line of ClearID® tests for greatly improved cancer detection and monitoring via a patient-friendly blood draw, and a suite of proprietary, distributable LiquidBiopsy® platforms and consumables for deployment in hospitals and third party diagnostic labs. Cynvenio is based in Westlake Village, California. For more information, please visit www.cynvenio.com, www.clearidmonitoring.com, and www.liquidbiopsy.com.
LiquidBiopsy® and ClearID® are registered trademarks of Cynvenio Biosystems, Inc.